Drug Profile
INCB 3284
Alternative Names: INCB3284Latest Information Update: 28 May 2010
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Anti-inflammatories; Small molecules
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Insulin resistance; Rheumatoid arthritis
Most Recent Events
- 23 Nov 2005 Incyte and Pfizer have entered into an exclusive worldwide agreement for the development, manufacture and marketing of INCB 3284 and other CCR2 antagonists
- 08 Aug 2005 Phase-II clinical trials in Insulin resistance in USA (PO)
- 04 May 2005 Phase-II clinical trials in Rheumatoid arthritis in USA (PO)